News

New Webinar: Acute and longterm neurorecovery after TBI

Don’t miss the second EVER Pharma Webinar on 18th May from 12:00-13:30 (MEZ).
read more

New Meta-Analysis confirms Efficacy of Cerebrolysin®

Cerebrolysin® after moderate to severe traumatic brain injury
read more
1 44 45 46 47 48 70
06.06.2025

AMN CONGRESS IN BANGKOK, THAILAND

04 – 05 July, 2025, Pullmann Bangkok King Power
Read more
22.04.2025

ESOC 2025 - Visit the EVER Pharma Symposium

Evidence from 3 new studies
Read more
15.04.2025

Interview with 2 Aphasia Experts

Watch the Video now!
Read more
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.